SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Contango Silver & Gold Inc. issued a press release on August 13, 2026 announcing its financial results for the quarter ended June 30, 2026, including quarterly production results (8,627 oz gold, 10,319 oz silver sold), net income of $4.8M, cash position of $89.0M, and production guidance for 2026-2027 (40,000-45,000 oz in 2026; 75,000-80,000 oz in 2027).
View raw filing on EDGAR →This is a preliminary earnings announcement for the six months ended June 30, 2026, disclosing expected total revenue of approximately US$3.85–3.90 million and providing an operating update on OwlPay Harbor's commercial scaling with significant payment volume growth metrics (107.6% month-over-month in July, annualized run-rate of ~US$130 million). The company explicitly states it will release complete unaudited first half 2026 financial results on August 21, 2026, and management provides forward-looking commentary on business performance and scaling trajectory. This is a discrete earnings event, not a periodic financial report itself.
View raw filing on EDGAR →Star Equity Holdings issued a press release on August 14, 2026 announcing financial results for the three months ended June 30, 2026, disclosing revenue of $54.9 million (up 54.6% YoY), gross profit of $22.8 million, net loss per diluted share of $0.66, and adjusted EBITDA of $2.2 million. The press release is furnished as Exhibit 99.1 to the 8-K Item 2.02 filing, which is the standard disclosure vehicle for quarterly earnings announcements.
View raw filing on EDGAR →This is a press release announcing the publication and presentation of BW LPG's Q2 2026 Financial Report on August 28, 2026. While the exhibit itself is an announcement of the upcoming earnings release rather than the results themselves, it functions as a discrete event disclosure of material quarterly financial results. The company explicitly states it "announces today that it will publish its Q2 2026 Financial Report" and will host an earnings presentation led by the CEO and CFO, which is the standard form of earnings disclosure for a public company.
View raw filing on EDGAR →The 8-K discloses Digi Power X's financial results for Q2 2026 (ended June 30, 2026) via Item 2.02, including revenue of $6.6 million, net loss of $14.4 million, and positive Adjusted EBITDA of $3.3 million. The press release (Exhibit 99.1) provides detailed quarterly financial results, operational highlights, and a 2027 outlook, which is the hallmark of an earnings release disclosure.
View raw filing on EDGAR →This is a straightforward earnings release disclosing Q2 2026 and first-half 2026 financial results for Greenland Technologies. The filing explicitly states "On August 14, 2026, the Company issued a press release announcing its financial results for the quarter ended June 30, 2026," with the full press release furnished as Exhibit 99.1. The press release reports strong results including 37.6% revenue growth, return to profitability ($4.9M net income vs. $2.8M loss in prior year), and expanded gross margins, making it material to investors.
View raw filing on EDGAR →StablecoinX Inc. issued a press release on August 14, 2026 announcing financial results for the second quarter of fiscal year 2026, disclosing total assets of $232.6 million, ENA treasury holdings of approximately 3.0 billion tokens valued at $218.4 million, and operational metrics including $62,372 in infrastructure services revenue. This is a standard quarterly earnings disclosure furnished under Item 2.02 with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →Emmaus Life Sciences issued a press release on August 14, 2026 announcing its results of operations and financial condition for the three and six months ended June 30, 2026. The disclosure includes detailed financial statements (condensed consolidated statement of operations and balance sheets), revenue analysis showing a 124% increase in net revenues due to the NIT license arrangement, operating expense reductions, and net income of $1.3 million for the quarter. This is a standard quarterly earnings release with material financial results that would affect a reasonable investor's assessment of the company's performance.
View raw filing on EDGAR →The filing discloses quarterly and six-month financial results for the period ended June 30, 2026 under Item 2.02 (Results of Operations and Financial Condition). The press release (Exhibit 99.1) presents selected financial highlights including revenues, operating expenses, operating income/loss, and net income comparisons to prior-year periods. This is a standard earnings release disclosure material to investors assessing the company's financial performance.
View raw filing on EDGAR →The filing discloses Jasper Therapeutics' financial results for the quarter ended June 30, 2026, including condensed consolidated statements of operations and balance sheets, along with a press release reporting Q2 2026 results and corporate updates. This is a standard earnings release disclosure under Item 2.02, furnished as Exhibit 99.1, reporting quarterly financial performance and operational milestones including the completed Kira Pharmaceuticals acquisition and $132 million PIPE financing.
View raw filing on EDGAR →Item 2.02 discloses unaudited financial and operating results for the six-month and three-month periods ended June 30, 2026, announced via press release on August 14, 2026. The filing includes condensed consolidated statements of operations, balance sheets, and detailed revenue, gross profit, and operating metrics. This is a standard earnings release disclosure required under Item 2.02 of Form 8-K.
View raw filing on EDGAR →This is a CEO letter to shareholders issued August 13, 2026, disclosing SEALSQ's preliminary unaudited H1 2026 financial results: revenue of approximately $11 million (120% YoY growth from $5 million in H1 2025), cash position of $485 million, and reaffirmed full-year 2026 guidance of 50–100% revenue growth. While framed as a strategic letter rather than a formal press release, it contains the core elements of an earnings disclosure—preliminary financial results, year-over-year comparisons, and forward guidance—making it functionally equivalent to an earnings release. The material growth metrics and liquidity position would affect a reasonable investor's assessment.
View raw filing on EDGAR →This is a CEO letter to shareholders issued August 13, 2026, disclosing preliminary unaudited H1 2026 financial results: revenue of approximately $11 million (120% YoY growth from $5 million in H1 2025), cash position of $485 million as of June 30, 2026, and reaffirmed full-year 2026 guidance of 50–100% revenue growth. While framed as a strategic letter rather than a formal earnings press release, it contains material preliminary financial results for the first half of 2026 and forward guidance, making it functionally equivalent to an earnings disclosure under Item 2.02.
View raw filing on EDGAR →The 8-K discloses Q2 2026 financial results for 1847 Holdings LLC via a press release filed under Item 2.02 (Results of Operations and Financial Condition). The filing reports continuing operations revenue of $1.6M, operating loss improvement of 57% year-over-year, gross margin expansion of 600 basis points, and positive operating cash flow of $712K for the first half of 2026. While the press release also discusses the CMD sale process and non-binding offers, the primary disclosure is the quarterly financial results, which is material to investors assessing the company's operational performance.
View raw filing on EDGAR →The 8-K discloses Corvex's financial results for Q2 2026 (quarter ended June 30, 2026) under Item 2.02 Results of Operations and Financial Condition. The press release (Exhibit 99.1) reports Q2 revenue of $3.8 million, net loss of $(12.8) million, and provides detailed financial highlights and business metrics including contracted annualized recurring revenue of approximately $22 million. This is a standard quarterly earnings release disclosure.
View raw filing on EDGAR →The 8-K discloses Citius Pharmaceuticals' fiscal third quarter 2026 financial results under Item 2.02 (Results of Operations and Financial Condition). The press release reports Q3 revenues of $1.5 million and nine-month revenues of $7.1 million from LYMPHIR commercial sales, along with detailed financial statements showing gross profit, operating expenses, and net loss figures. This is a standard quarterly earnings disclosure with attached financial tables and operational highlights.
View raw filing on EDGAR →On August 14, 2026, Citius Oncology, Inc. issued a press release announcing its results of operations for the third quarter of fiscal 2026, disclosing revenues of $1.5 million for Q3 2026 (compared to $0 in Q3 2025) and $7.1 million for the nine-month period, along with a net loss of $8.9 million for Q3 and condensed consolidated financial statements.
View raw filing on EDGAR →The filing discloses Allarity Therapeutics' financial results for the second quarter ended June 30, 2026, via a press release dated August 14, 2026. Item 2.02 explicitly covers "Results of Operations and Financial Condition," and the press release reports Q2 2026 financial metrics including cash position ($26.9 million), R&D expenses ($1.3 million), G&A expenses ($1.3 million), and comprehensive loss ($3.7 million), alongside operational highlights such as completion of Phase 3 manufacturing, patent grant, and CLIA certification. This is a standard quarterly earnings disclosure.
View raw filing on EDGAR →This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02, with the press release attached as Exhibit 99.1. The disclosure includes financial highlights (revenue, cash, gross profit, net loss, adjusted EBITDA), business highlights, and condensed consolidated balance sheet data. While the company reports declining revenue (11% decrease) and continued net losses, the disclosure is a routine quarterly financial results announcement material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →The filing discloses authID's financial results for Q2 2026 ended June 30, 2026, via a press release dated August 14, 2026, furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02. While the press release also mentions the Board's evaluation of strategic and financing alternatives, the primary disclosed event is the earnings release itself, which is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →VerifyMe issued a press release on August 14, 2026, disclosing financial results for Q2 2026 and the six-month period ended June 30, 2026. The filing includes consolidated balance sheets, statements of operations, and key financial metrics (revenue of $1.9M vs. $4.5M prior year, net loss of ($0.5)M, cash position of $5.1M). This is a standard earnings release disclosure under Item 2.02, furnished as Exhibit 99.1.
View raw filing on EDGAR →This is a comprehensive earnings release for Azul S.A.'s second quarter 2026 results, disclosing detailed financial and operating metrics including revenue (R$4.98 billion), EBITDA (R$510.1 million), net loss (R$1.04 billion), and key operational data. The filing explicitly states "Azul Reports 2Q26 Results" and presents consolidated financial statements with year-over-year comparisons, making it a material earnings disclosure that would affect investor assessment of the airline's financial performance and operational trajectory.
View raw filing on EDGAR →This is a quarterly earnings release for Braskem S.A. disclosing 2Q26 financial results. The document explicitly states "Braskem reports Recurring EBITDA of approximately US$1.0 billion in 2Q26" and provides detailed consolidated financial overview including revenue, COGS, EBITDA, and cash flow metrics across all business segments. The filing includes a conference call schedule and investor relations contact information typical of earnings announcements.
View raw filing on EDGAR →This is a press release announcing Sigma Lithium's second quarter 2026 financial results, disclosing record revenues of US$55 million, record EBITDA margin of 47%, and significant operational metrics including production volumes and cost reductions. The document explicitly states "announces the Company's results for the three months ended June 30, 2026" and includes detailed financial highlights, operational updates, and production guidance—all hallmarks of a quarterly earnings release. Material to investors as it demonstrates strong profitability and operational progress.
View raw filing on EDGAR →This 6-K furnishes an earnings conference call presentation for Braskem's 2Q26 results, dated August 14, 2026. The document discloses consolidated recurring EBITDA of US$1,043 million for 2Q26 (up from US$192 million in 1Q26), segment-by-segment performance metrics, cash flow analysis, and forward guidance on spreads and industry conditions. The presentation explicitly covers "2Q26 CONSOLIDATED PERFORMANCE" with detailed financial results and is titled "EARNINGS CONFERENCE CALL 2Q26," making it a discrete earnings event rather than a periodic financial report.
View raw filing on EDGAR →The exhibit is a press release dated August 13, 2026, announcing Euroseas Ltd.'s financial results for Q2 2026 and the first half of 2026, including detailed revenue ($56.5M for Q2, $112.3M for H1), net income ($33.2M and $65.7M respectively), EPS ($4.77 basic for Q2), and operational metrics. The release also declares a quarterly dividend of $0.80 per share. This is a discrete earnings announcement, not a periodic financial report, and would materially affect investor assessment of the company's financial performance and capital allocation.
View raw filing on EDGAR →VirTra issued a press release on August 13, 2026 announcing financial results for Q2 and six months ended June 30, 2026, with detailed revenue, gross profit, net income, and EPS figures. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1. The disclosure shows material year-over-year declines (revenue down 35% for six months, net loss of $1.6M vs. prior year income of $1.4M), making this a material earnings release that would affect investor assessment of the company's financial performance.
View raw filing on EDGAR →This is a clear earnings release disclosing Q2 2026 and 1H 2026 financial results for BIO-key International. The press release (Exhibit 99.1) announces revenues of $1.9M in Q2'26 (up 13% YoY), gross margin improvement to 87%, and a 51% reduction in net loss to $(577K). The filing is made under Item 2.02 (Results of Operations and Financial Condition) and includes detailed financial statements and management commentary on performance and outlook.
View raw filing on EDGAR →Professional Diversity Network disclosed financial results for the three and six months ended June 30, 2026, including revenue, costs, net loss, balance sheet, and cash flow information via a press release attached as Exhibit 99.1.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 14, 2026 under Item 2.02. The press release (Exhibit 99.1) announces financial results including R&D expenses of $5.5M, G&A expenses of $2.1M, and a net loss of $7.6M for the quarter, along with unaudited condensed consolidated balance sheets and statements of operations. The disclosure is material as it reports the company's quarterly financial performance and operational highlights including positive interim MIRACLE trial data.
View raw filing on EDGAR →Clene Inc. issued a press release on August 14, 2026, announcing its second quarter 2026 financial results for the quarter ended June 30, 2026, including condensed consolidated statements of operations and balance sheets. The disclosure includes quarterly revenue, operating expenses, net loss of $13.4 million ($1.08 per share), and cash position of $9.7 million as of June 30, 2026. This is a standard earnings release filed under Item 2.02 with financial statements attached as Exhibit 99.1.
View raw filing on EDGAR →Track Group issued a press release on August 14, 2026, announcing financial results for the third fiscal quarter ended June 30, 2026. The disclosure includes detailed quarterly revenue ($9.09 million), net income ($22.44 million, driven primarily by a $23.46 million gain on troubled debt restructuring), earnings per share ($0.68 diluted), and non-GAAP metrics (Adjusted EBITDA of $1.47 million). The press release is attached as Exhibit 99.1 and constitutes a standard quarterly earnings announcement under Item 2.02.
View raw filing on EDGAR →This is a standard earnings release for Q2 2026 ended June 30, 2026, filed on August 14, 2026. The press release discloses quarterly financial results including net sales ($23.2M vs. $39.2M prior year), gross profit margins, SG&A expenses, net loss ($10.6M vs. $16.9M), and Adjusted EBITDA. The full text is furnished as Exhibit 99.1 and incorporated by reference in Item 2.02, which is the standard Item for results of operations and financial condition disclosures. Material to investors as it shows significant revenue decline and ongoing losses.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 (three months ended June 30, 2026) and year-to-date results. The Item 2.02 disclosure explicitly states "The LGL Group, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026," with the press release attached as Exhibit 99.1. The filing includes detailed financial statements, revenue analysis, segment results, and management commentary on operational performance, making this a standard quarterly earnings disclosure material to investors.
View raw filing on EDGAR →The filing discloses quarterly financial results for the six months ended June 30, 2026, with a press release issued on August 14, 2026. The press release includes condensed consolidated statements of operations, balance sheets, and supplemental financial information, presenting net loss of $3.7 million for the period. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and operational progress across its land development, commercial real estate, and agribusiness segments.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 (three and six months ended June 30, 2026). The Item 2.02 disclosure explicitly states the company "issued a press release to report financial results for the quarter ended June 30, 2026," with the press release furnished as Exhibit 99.1. The exhibit contains detailed financial results including revenue growth of 12.8% to $3.6 million, gross profit, operating expenses, and net loss figures, along with segment performance metrics and management commentary on business operations and strategy.
View raw filing on EDGAR →Item 2.02 discloses preliminary, unaudited operating information for Q2 2026 and July 2026 operating indicators in a shareholder update furnished as Exhibit 99.1. While labeled "preliminary" and "unaudited" rather than a formal earnings release, the disclosure provides quantitative and qualitative operating results (customer acquisition metrics, product sales volumes, cost reductions, subscription order percentages) that constitute a material update on financial condition and results of operations for the quarter ended June 30, 2026.
View raw filing on EDGAR →The filing discloses Q2 2026 financial results for Lantern Pharma via a press release dated August 14, 2026 (Item 2.02). The press release reports second quarter loss from operations of approximately $3.5 million (down 25% year-over-year), cash position of $7.4 million as of June 30, 2026, and gross proceeds of $4.4 million from a registered direct offering. While the filing also includes operational updates on clinical trials and the establishment of Open Medicine AI as a separate company, the primary disclosure mechanism is the earnings release attached as Exhibit 99.1.
View raw filing on EDGAR →The 8-K discloses quarterly financial results for Q2 2026 under Item 2.02 (Results of Operation and Financial Condition). The press release reports revenue of $3.07 million (53% YoY growth), gross profit, operating loss of $1.72 million, and net loss of $1.75 million, along with segment performance and management commentary on strategic priorities. This is a standard earnings release disclosure material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →The 8-K discloses Safe Pro Group's Q2 2026 financial results under Item 2.02 (Results of Operations and Financial Condition), with a press release attached as Exhibit 99.1. The filing reports record revenue growth of 1,336% year-over-year ($1.33M vs. $92.8K), AI subsidiary revenue surge of 3,084%, and 75% AI gross margins, along with multiple government contract awards. This is a standard earnings release disclosure material to investors assessing the company's financial performance and growth trajectory.
View raw filing on EDGAR →The filing discloses Boost Run Inc.'s financial and operational results for Q2 2026 (quarter ended June 30, 2026) via Item 2.02 (Results of Operations and Financial Condition). The earnings press release (Exhibit 99.1) reports Q2 revenue of $31.1 million (270% YoY increase), total contract value of $1.9 billion, and $120.2 million in unrestricted cash. This is the company's first earnings announcement as a public company following its May 8, 2026 business combination. The disclosure is material to investors assessing the registrant's financial performance and growth trajectory.
View raw filing on EDGAR →PAVmed issued a press release on August 14, 2026, announcing financial results for the fiscal quarter ended June 30, 2026, including operating expenses of $7.1 million, GAAP net loss of $5.5 million ($(0.87) per share), and cash position of $3.8 million as of June 30, 2026. The disclosure is filed under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.
View raw filing on EDGAR →The 8-K discloses first quarter fiscal 2027 financial results for PCS Edventures!, Inc. via a press release dated August 14, 2026 (Exhibit 99). The filing reports revenue of $1.74 million (down 28.2% year-over-year), gross margin of 62.8%, net income before tax of $0.10 million, and cash position of $2.65 million. This is a standard earnings release disclosure under Item 7.01 (Regulation FD Disclosure) with the press release furnished as Exhibit 99.
View raw filing on EDGAR →The filing discloses financial results for Q2 2026 (three and six months ended June 30, 2026) via Item 2.02, including revenues, R&D expenses, G&A expenses, and net loss figures. The press release (Exhibit 99.1) announces "Second Quarter 2026 Business and Clinical Development Highlights and Financial Results," presenting both operational milestones and quarterly financial metrics. This is a standard earnings release disclosure material to investors assessing the company's financial performance and clinical progress.
View raw filing on EDGAR →This exhibit is a press release announcing Foresight's financial results for Q2 2026 and H1 2026, including revenues, operating expenses, net loss, balance sheet highlights, and cash flow statements. The disclosure includes both GAAP and non-GAAP metrics and is dated August 14, 2026, consistent with a quarterly earnings announcement. While the company is unprofitable and burning cash, the disclosure of quarterly and interim financial results is a standard earnings release event.
View raw filing on EDGAR →The 8-K discloses Motorsport Games' financial results for Q2 2026 (quarter ended June 30, 2026) via Item 2.02 and an attached press release (Exhibit 99.1). The press release reports revenues of $3.5 million in Q2 2026 (up 36.6% YoY), six consecutive quarters of profitability, gross margin expansion to 84.7%, and significant growth in RaceControl subscription revenues (up 348.9% YoY). This is a standard quarterly earnings release material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →The 8-K discloses financial results for the three and six months ended June 30, 2026, with a press release attached as Exhibit 99.1. Item 2.02 explicitly states "On August 14, 2026, we issued a press release regarding our financial results for the three and six months ended June 30, 2026." The filing includes consolidated statements of comprehensive loss, revenue comparisons, gross profit analysis, and non-GAAP reconciliations—all standard components of an earnings release.
View raw filing on EDGAR →The filing discloses second quarter 2026 financial results for Barfresh Food Group, including revenue of $4.7 million (190% YoY increase), gross loss of $150,000, net loss of $1.9 million, and revised full-year 2026 guidance of $23–26 million revenue and negative $1.0–2.0 million Adjusted EBITDA. The press release (Exhibit 99.1) is the primary disclosure under Item 2.02 (Results of Operations and Financial Condition), which is the standard vehicle for earnings releases. The filing includes management commentary, financial tables, and forward-looking statements typical of quarterly earnings announcements.
View raw filing on EDGAR →The 8-K discloses Item 2.02 (Results of Operations and Financial Condition) with a press release dated August 14, 2026 reporting Q2 2026 financial results for Enveric Biosciences. The filing explicitly states the company "reported financial results for the second quarter ended June 30, 2026" and provides specific metrics including net loss of $3.0 million, loss per share of $0.76, and cash-on-hand of $8.3 million. This is a standard quarterly earnings release disclosure.
View raw filing on EDGAR →The filing discloses Greenlane's financial results for the second quarter ended June 30, 2026 via Item 2.02 (Results of Operations and Financial Condition). The press release reports Q2 2026 net revenue of $82K, operating loss of $(3.3)M, and net loss of $(24.8)M, along with digital asset holdings and strategic metrics. This is a standard quarterly earnings disclosure material to investors assessing the company's financial performance and digital asset treasury strategy.
View raw filing on EDGAR →